We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

New Optical Biopsy System That Detects Liver Cancer Could Help Surgeons Pinpoint Best Place for Biopsy

By HospiMedica International staff writers
Posted on 10 Jan 2022
Print article
Image: New Optical Biopsy System That Detects Liver Cancer Could Help Surgeons Pinpoint Best Place for Biopsy (Photo courtesy of Evgenii Zherebtsov, Orel State University)
Image: New Optical Biopsy System That Detects Liver Cancer Could Help Surgeons Pinpoint Best Place for Biopsy (Photo courtesy of Evgenii Zherebtsov, Orel State University)

Researchers have developed an optical biopsy system that can distinguish between cancerous and healthy liver tissue.

The new technology developed by a research team from Orel State University (Oryol, Russia) could make it easier to diagnose liver cancer, which is the sixth most common cancer globally. The optical biopsy system can reliably distinguish between cancerous and healthy cells in mouse models. The system also showed promise in preliminary tests conducted in people with suspected liver cancer.

The researchers designed the new device after the surgeons with which they were collaborating noted how difficult it is to perform needle biopsies in exactly the right location. Early-stage tumors can be hard to pinpoint when inserting a tiny hollow needle into the liver to acquire a tissue sample. If the needle is placed incorrectly and misses the tumor, it could lead to an incorrect diagnosis.

The new optical biopsy system combines diffuse reflectance spectroscopy and lifetime fluorescence measurements to evaluate markers related to cellular metabolism, which differs between healthy and cancerous cells. This could help surgeons see, in real time, where the cancer is so that they can identify the best place to acquire a tissue sample. Diffuse reflectance spectroscopy reveals tissue properties based on how they reflect light. Fluorescence lifetime analysis exposes tissues to a wavelength of light that induces fluorescence and then measures how long that fluorescence takes to fade. The timing of the fluorescence decay depends on the presence of molecules that are important in metabolism.

With a focus on using the new instrument to guide future biopsies in the clinic, the researchers selected compact, modern components for the device. The 1-millimeter-diameter probe is compatible with a standard 17.5G biopsy needle and has separate optical channels for diffuse reflectance spectroscopy and fluorescence lifetime measurements. To assess the sensitivity of the assembled system, the researchers first measured known solutions of molecules that play key roles in metabolism. Once they obtained satisfactory results, they then performed experiments in a mouse model with liver cancer and preliminary measurements in patients with suspected liver cancer. The researchers found that their instrument and the parameters they measured could reliably distinguish liver cancer tissue, healthy liver tissue and the metabolically changed liver tissues that surround a tumor.

The researchers plan to continue measuring fluorescence lifetime parameters in patients with different types of tumors at different stages to generate real-time diagnostic classifiers. This will also make it possible to apply advanced machine learning methods that could help surgeons make clinical decisions during a biopsy procedure.

“The instrument is designed to be compatible with the needles currently used for liver biopsies,” said Evgenii Zherebtsov, a member of the research team. “It could thus one day help surgeons more precisely navigate the biopsy instrument to decrease the number of errors in taking tissue samples that are used for diagnosis.”

“Optical biopsy methods like the one we developed make it possible to differentiate healthy and tumor tissues with a high degree of accuracy,” said Elena V. Potapova, who assisted Zherebtsov. “Although our system was specifically designed for use in abdominal surgery, our results show that similar technologies could be useful for other medical applications.”

Related Links:
Orel State University 

Gold Supplier
12-Channel ECG
CFM Device
EEGDigiTrack CFM/aEEG Devices
X-Ray Protection
X-Ray Protective Clothing and Accessories

Print article
FIME - Informa



view channel
Image: The AI tool can also tackle dangerous inequalities in heart attack diagnosis (Photo courtesy of Freepik)

AI Algorithm Integrates Cardiac Troponin Test Results with Clinical Data to Quickly Rule out Heart Attacks in Patients

The accepted standard for diagnosing myocardial infarction, or heart attack, involves assessing the blood for troponin levels. However, this approach applies the same benchmark for all patients, failing... Read more

Critical Care

view channel
Image: New technology gives patients the power to heal chronic wounds using their own blood (Photo courtesy of RedDress)

POC Solution Creates In Vitro Blood Clots from Patient’s Own Whole Blood in Real-Time to Treat Post-Surgical Wounds

Blood clots are a natural mechanism of the body's healing process. However, for chronic wounds resulting from diabetes and other conditions, blood is unable to reach these areas, hampering the initiation... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: IntelliSep is the first FDA-cleared diagnostic tool to assess cellular host response to aid in identifying ED patients with sepsis (Photo courtesy of Cytovale)

Rapid Microfluidic Test Demonstrates Efficacy as Diagnostic Aid to Improve Sepsis Triage in ED

Sepsis is the primary cause of mortality worldwide, accounting for over 350,000 fatalities annually in the United States alone, a figure that surpasses deaths from opioid overdoses, prostate cancer, and... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.